Roy Fleischmann comments on the results of the SELECT-MONOTHERAPY and SELECT-NEXT trials, which provide further evidence for the benefits of upadacitinib in patients with RA (6:18).
26-06-2018 | Rheumatoid arthritis | EULAR 2018 | Video
26-06-2018 | Rheumatoid arthritis | EULAR 2018 | Video
Roy Fleischmann comments on the results of the SELECT-MONOTHERAPY and SELECT-NEXT trials, which provide further evidence for the benefits of upadacitinib in patients with RA (6:18).